Veliparib With or Without Radiation Therapy, Carboplatin, and Paclitaxel in Patients With Stage III Non-small Cell Lung Cancer That Cannot Be Removed by Surgery



Status:Active, not recruiting
Conditions:Lung Cancer, Cancer, Cancer, Cancer, Cancer
Therapuetic Areas:Oncology
Healthy:No
Age Range:18 - Any
Updated:3/16/2019
Start Date:June 20, 2011

Use our guide to learn which trials are right for you!

A Dose Finding Study Followed by Phase II Randomized, Placebo-Controlled Study of Veliparib (ABT-888) Added to Chemoradiotherapy With Carboplatin and Paclitaxel for Unresectable Stage III Non-small Cell Lung Cancer (NSCLC), (NCI Study Number 8811)

This phase I/II partially randomized trial studies the side effects and best dose of
veliparib when given together with radiation therapy, carboplatin, and paclitaxel and to see
how well it works in treating patients with stage III non-small cell lung cancer that cannot
be removed by surgery. Veliparib may stop the growth of tumor cells by blocking some of the
enzymes needed for cell growth. Radiation therapy uses high energy x-rays to kill tumor cells
and shrink tumors. Drugs used in chemotherapy, such as carboplatin and paclitaxel, work in
different ways to stop the growth of tumor cells either by killing the cells, by stopping
them from dividing, or by stopping them from spreading. It is not yet known whether radiation
therapy, carboplatin, and paclitaxel are more effective with or without veliparib in treating
non-small cell lung cancer.

PRIMARY OBJECTIVES:

I. To establish the maximum tolerated dose (MTD) and the recommended phase II dose of ABT-888
(veliparib) when given concurrently with standard carboplatin/paclitaxel and radiotherapy in
patients with unresectable stage III non-small cell lung cancer (NSCLC). (Phase I) II. To
assess whether carboplatin/paclitaxel plus ABT-888 compared with carboplatin/paclitaxel plus
placebo improves progression-free survival (PFS) in patients with unresectable stage III
NSCLC. (Phase II) III. To compare overall survival (OS) in patients treated with
carboplatin/paclitaxel and radiotherapy plus ABT-888 to those treated with carboplatin,
paclitaxel and radiotherapy plus placebo. (Phase II) IV. To assess the response rate
(confirmed and unconfirmed, complete and partial responses) and disease control rate in the
subset of patients with measurable disease by Response Evaluation Criteria in Solid Tumors
(RECIST) criteria. (Phase II) V. To assess the safety and toxicity profile of the regimen.
(Phase II)

SECONDARY OBJECTIVES:

I. To collect tumor tissue from pretreatment biopsies (archival samples) for biomarker
studies, including poly (ADP-ribose) polymerase 1 (PARP) activity by measuring the levels of
poly-ADP-ribose, gamma-H2A histone family, member X (gamma-H2AX), and messenger ribonucleic
acid (mRNA) expression levels of deoxyribonucleic acid (DNA) repair enzymes such as excision
repair cross-complementing rodent repair deficiency, complementation group 1 (ERCC1)/x-ray
repair complementing defective repair in Chinese hamster cells 1 (XRCC1).

II. To collect blood samples for evaluation of gamma-H2AX (circulating tumor cells) and other
relevant future studies.

OUTLINE: This is a phase I, dose-escalation study of veliparib followed by a randomized phase
II study.

PHASE I:

INDUCTION THERAPY: Patients undergo 3-dimensional conformal radiation therapy (3D-CRT) once
daily (QD), 5 days a week, for 6 weeks. Patients also receive veliparib orally (PO) twice
daily (BID) on days 1-43 and carboplatin intravenously (IV) over 30 minutes and paclitaxel IV
over 1 hour on days 1, 8, 15, 22, 36, and 43 in the absence of disease progression or
unacceptable toxicity. Patients without disease progression after completion of
chemoradiotherapy undergo consolidation therapy.

CONSOLIDATION THERAPY: Beginning within 4-6 weeks of chemotherapy and radiation therapy,
patients receive veliparib PO BID on days 1-7 (course 1) and 22-28 (course 2) and carboplatin
IV over 30 minutes and paclitaxel IV over 3 hours on day 1 and on day 22 of course 2.
Treatment repeats every 21 days for 2 courses in the absence of disease progression or
unacceptable toxicity.

PHASE II: Patients are randomized to 1 of 2 treatment arms.

ARM I: Patients undergo 3D-CRT and receive veliparib, carboplatin, and paclitaxel as in Phase
I induction and consolidation therapy.

ARM II: Patients undergo 3D-CRT as in arm I. Patients also receive placebo PO BID on days
1-43 and carboplatin and paclitaxel as in Phase I. Within 4-6 weeks after completion of
chemotherapy and radiation therapy, patients receive placebo on days 1-7 and carboplatin and
paclitaxel as in Phase I.

After completion of study treatment, patients are followed up every 4 months for first 2
years and then every 6 months until 5 years.

Inclusion Criteria:

- Patients must have histologically or cytologically-proven new diagnosis of
unresectable stage IIIA/IIIB*, non-small cell lung cancer (adenocarcinoma,
bronchioloalveolar cell carcinoma, large cell carcinoma, squamous cell carcinoma, or
mixed)

- Per the American Joint Committee on Cancer (AJCC) 7th edition, pleural and
pericardial are now considered stage M1a disease; when pleural fluid is visible
on the computed tomography (CT) scan or on a chest x-ray, a thoracentesis is
required to confirm that the pleural fluid is cytologically negative; patients
with exudative pleural effusions are excluded, regardless of cytology; patients
with effusions that are minimal (i.e. not visible on chest x-ray) that are too
small to safely tap are eligible; a small effusion that has positive
fludeoxyglucose F 18 (FDG) uptake on positron emission tomography (PET) has to be
proven to be malignant per standard of care diagnostic procedures for the patient
to be excluded

- Patients must have measurable or non-measurable disease documented by CT, magnetic
resonance imaging (MRI) or PET/CT; the CT from a combined PET/CT may be used to
document only non-measurable disease unless the scan is of diagnostic quality;
measurable disease must be assessed by CT within 28 days prior to registration;
pleural effusions, ascites and laboratory parameters are not acceptable as the only
evidence of disease; non-measurable disease must be assessed within 42 days prior to
registration; all disease must be assessed and documented on the Baseline Tumor
Assessment Form

- Patients with brain metastases are ineligible; all patients must have a pretreatment
CT or MRI scan of the brain to evaluate for central nervous system (CNS) disease
within 42 days prior to registration

- Patients must not have received any prior systemic therapy (chemotherapy or other
biologic therapy) for lung cancer

- Patients must not have received prior chest radiation therapy for NSCLC

- Patients must not have had a previous surgical resection; however, patients may have
undergone exploratory thoracotomy, mediastinoscopy, excisional biopsy or similar
surgery for the purpose of determining the diagnosis, stage or potential resectability
of newly diagnosed lung tumor; at least 28 days must have elapsed since thoracic
surgery (excluding mediastinoscopy or other minor surgeries) and patients should have
recovered from all associated toxicities at the time of registration; patients must
not be planning to undergo a minor surgical procedure while on this study

- Patients must have Zubrod performance status 0-1

- Patients must have tumor tissue available for submission to assess gene expression of
ERCC1 and XRCC1; patients must also be offered participation in banking for future use
of specimens

- Absolute neutrophil count >= 1,500/mcl

- Platelets >= 100,000/mcl

- Hemoglobin >= 9.0 g/dl

- Total bilirubin within institutional upper limit of normal (IULN)

- Serum glutamic oxaloacetic transaminase (SGOT) (aspartate aminotransferase [AST]) or
serum glutamate pyruvate transaminase (SGPT) (alanine aminotransferase [ALT]) =< 2.5 x
IULN

- Patients must not be pregnant or nursing; women/men of reproductive potential must
have agreed to use an effective contraceptive method; a woman is considered to be of
"reproductive potential" if she has had menses at any time in the preceding 12
consecutive months; in addition to routine contraceptive methods, "effective
contraception" also includes heterosexual celibacy and surgery intended to prevent
pregnancy (or with a side-effect of pregnancy prevention) defined as a hysterectomy,
bilateral oophorectomy or bilateral tubal ligation; however, if at any point a
previously celibate patient chooses to become heterosexually active during the time
period for use of contraceptive measures outlined in the protocol, he/she is
responsible for beginning contraceptive measures

- Patients must have a serum creatinine =< the IULN AND measured or calculated
creatinine clearance >= 60 cc/min using the Cockroft-Gault formula

- Patients must have pulmonary function tests (PFTs) including forced expiratory volume
in 1 second (FEV1) within 84 days prior to registration; for FEV1, the best value
obtained pre- or post-bronchodilator must be >= 1.2 liters/second and/or >= 50%
predicted

- Patients may not be planning to receive any other investigational agents

- Patients must not have more than 10% weight loss in the past 6 months

- Patients must not have a history of allergic reactions attributed to compounds of
similar chemical or biologic composition to ABT-888, carboplatin, paclitaxel or other
agents used in study

- No other prior malignancy is allowed except for the following: adequately treated
basal cell or squamous cell skin cancer, in situ cervical cancer, adequately treated
stage I or II cancer from which the patient is currently in complete remission, or any
other cancer from which the patient has been disease free for five years

- Patient must not have any uncontrolled intercurrent illness including, but not limited
to ongoing or active infection, symptomatic congestive heart failure, unstable angina
pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would
limit compliance with study requirements

- Patients must not currently have a > grade 1 symptomatic neuropathy-sensory (National
Cancer Institute [NCI] Common Terminology Criteria for Adverse Events [CTCAE] version
4.0)

- Patients must not have a history of seizures

- Patients must not have any known immune deficiencies; patients with immune deficiency
are at increased risk of lethal infections when treated with marrow-suppressive
therapy; therefore, known human immunodeficiency virus (HIV) positive patients
receiving combination anti-retroviral therapy are excluded from the study

- Patients must be able to swallow whole capsules

- Prestudy history and physical must be obtained within 28 days prior to registration

- All patients must be informed of the investigational nature of this study and must
sign and give written informed consent in accordance with institutional and federal
guidelines

- As a part of the Oncology Patient Enrollment Network (OPEN) registration process the
treating institution's identity is provided in order to ensure that the current
(within 365 days) date of institutional review board approval for this study has been
entered in the system

- REGISTRATION #2 - PRIOR TO CONSOLIDATION CHEMOTHERAPY:

- REGISTRATION #2 - PRIOR TO CONSOLIDATION CHEMOTHERAPY: Patients must have completed
chemoradiotherapy per protocol and at least four weeks but no more than six weeks must
have elapsed from the last day of induction therapy (the last day of radiation)

- REGISTRATION #2 - PRIOR TO CONSOLIDATION CHEMOTHERAPY: Patients must have undergone
restaging tests according to the study calendar and determined to have no evidence of
disease progression

- REGISTRATION #2 - PRIOR TO CONSOLIDATION CHEMOTHERAPY: Patients must have a serum
creatinine =< (IULN) AND measured of calculated creatinine clearance >= 60 cc/min
using the Cockroft-Gault formula

- REGISTRATION #2 - PRIOR TO CONSOLIDATION CHEMOTHERAPY: Absolute neutrophil count >=
1,500 mcl

- REGISTRATION #2 - PRIOR TO CONSOLIDATION CHEMOTHERAPY: Platelets >= 100,000/mcl

- REGISTRATION #2 - PRIOR TO CONSOLIDATION CHEMOTHERAPY: Hemoglobin >= 9.0 g/dl

- REGISTRATION #2 - PRIOR TO CONSOLIDATION CHEMOTHERAPY: Total bilirubin =< IULN

- REGISTRATION #2 - PRIOR TO CONSOLIDATION CHEMOTHERAPY: SGOT (AST) or SGPT (ALT) =< 2.5
x IULN

- REGISTRATION #2 - PRIOR TO CONSOLIDATION CHEMOTHERAPY: Patients must have Zubrod
performance status 0-1
We found this trial at
235
sites
Springfield, Illinois 62701
Principal Investigator: Edem S. Agamah
Phone: 217-525-2500
?
mi
from
Springfield, IL
Click here to add this to my saved trials
1500 E Duarte Rd
Duarte, California 91010
(626) 256-4673
Principal Investigator: Mihaela C. Cristea
Phone: 800-826-4673
City of Hope Comprehensive Cancer Center City of Hope is a leading research and treatment...
?
mi
from
Duarte, CA
Click here to add this to my saved trials
200 North Park Street
Kalamazoo, Michigan 49007
(269) 382-2500
Principal Investigator: Kathleen J. Yost
Phone: 616-391-1230
West Michigan Cancer Center In 1994, Borgess Health Alliance and Bronson Healthcare Group opened the...
?
mi
from
Kalamazoo, MI
Click here to add this to my saved trials
4805 Northeast Glisan Street
Portland, Oregon 97213
(503) 215-1111
Principal Investigator: Gary E. Goodman
Phone: 907-212-6871
Providence Portland Medical Center We strive to give those we serve exceptional, compassionate health care...
?
mi
from
Portland, OR
Click here to add this to my saved trials
4502 Medical Drive
San Antonio, Texas 78284
(210) 567-7000
University of Texas Health Science Center at San Antonio The University of Texas Health Science...
?
mi
from
San Antonio, TX
Click here to add this to my saved trials
Seattle, Washington 98104
Principal Investigator: Gary E. Goodman
Phone: 907-212-6871
?
mi
from
Seattle, WA
Click here to add this to my saved trials
'Aiea, Hawaii 96701
Principal Investigator: Jeffrey L. Berenberg
Phone: 808-586-2979
?
mi
from
'Aiea, HI
Click here to add this to my saved trials
98-1079 Moanalua Road
'Aiea, Hawaii 96701
Principal Investigator: Jeffrey L. Berenberg
Phone: 808-586-2979
?
mi
from
'Aiea, HI
Click here to add this to my saved trials
2226 Liliha Street
'Aiea, Hawaii 96701
?
mi
from
'Aiea, HI
Click here to add this to my saved trials
Aberdeen, Washington 98520
Principal Investigator: Gary E. Goodman
Phone: 907-212-6871
?
mi
from
Aberdeen, WA
Click here to add this to my saved trials
Ames, Iowa 50010
?
mi
from
Ames, IA
Click here to add this to my saved trials
Anaconda, Montana 59711
Principal Investigator: Benjamin T. Marchello
Phone: 406-969-6060
?
mi
from
Anaconda, MT
Click here to add this to my saved trials
Anchorage, Alaska 98508
Principal Investigator: Gary E. Goodman
Phone: 907-212-6871
?
mi
from
Anchorage, AK
Click here to add this to my saved trials
Anchorage, Alaska 99508
Principal Investigator: Gary E. Goodman
Phone: 907-212-6871
?
mi
from
Anchorage, AK
Click here to add this to my saved trials
Anchorage, Alaska 99508
Principal Investigator: Gary E. Goodman
Phone: 907-212-6871
?
mi
from
Anchorage, AK
Click here to add this to my saved trials
Anchorage, Alaska 99508
Principal Investigator: Gary E. Goodman
Phone: 907-212-6871
?
mi
from
Anchorage, AK
Click here to add this to my saved trials
Anchorage, Alaska 99508
Principal Investigator: Gary E. Goodman
Phone: 907-212-6871
?
mi
from
Anchorage, AK
Click here to add this to my saved trials
Anchorage, Alaska 99508
Principal Investigator: Gary E. Goodman
Phone: 907-212-6871
?
mi
from
Anchorage, AK
Click here to add this to my saved trials
Anchorage, Alaska 99508
Principal Investigator: Gary E. Goodman
Phone: 907-212-6871
?
mi
from
Anchorage, AK
Click here to add this to my saved trials
12605 East 16th Avenue
Aurora, Colorado 80045
720-848-0000
University of Colorado Hospital, Site Top medical professionals, superior medicine and progressive change make University...
?
mi
from
Aurora, CO
Click here to add this to my saved trials
2000 Ogden Ave
Aurora, Illinois 60504
(630) 978-6200
Principal Investigator: James R. Egner
Phone: 630-978-6212
Rush - Copley Medical Center Rush-Copley is proud to be the leading provider of health...
?
mi
from
Aurora, IL
Click here to add this to my saved trials
Ballwin, Missouri 63011
Principal Investigator: Jay W. Carlson
Phone: 888-221-4849
?
mi
from
Ballwin, MO
Click here to add this to my saved trials
265 Fremont St
Battle Creek, Michigan 49017
(269) 245-8166
Principal Investigator: Kathleen J. Yost
Phone: 616-391-1230
Bronson Battle Creek As a proud member of the Battle Creek community, we believe everyone...
?
mi
from
Battle Creek, MI
Click here to add this to my saved trials
Bellingham, Washington 98225
Principal Investigator: Gary E. Goodman
Phone: 907-212-6871
?
mi
from
Bellingham, WA
Click here to add this to my saved trials
Bemidji, Minnesota 56601
?
mi
from
Bemidji, MN
Click here to add this to my saved trials
Bend, Oregon 97701
Principal Investigator: Gary E. Goodman
Phone: 907-212-6871
?
mi
from
Bend, OR
Click here to add this to my saved trials
Beverly Hills, California 90211
Principal Investigator: Solomon I. Hamburg
Phone: 310-888-8680
?
mi
from
Beverly Hills, CA
Click here to add this to my saved trials
Billings, Montana 59101
Principal Investigator: Benjamin T. Marchello
Phone: 406-969-6060
?
mi
from
Billings, MT
Click here to add this to my saved trials
300 N. Seventh St.
Bismarck, North Dakota 58501
(701) 323-6000
Principal Investigator: Preston D. Steen
Phone: 712-252-0088
Sanford Bismarck Medical Center Whether your stay in our hospital is one day for same...
?
mi
from
Bismarck, ND
Click here to add this to my saved trials
Bloomington, Illinois 61701
Principal Investigator: James L. Wade
Phone: 217-876-4740
?
mi
from
Bloomington, IL
Click here to add this to my saved trials
1505 Eastland Drive
Bloomington, Illinois 61701
309-662-2102
Principal Investigator: James L. Wade
Phone: 309-243-3605
Illinois CancerCare-Bloomington Illinois CancerCare, P.C. is a comprehensive practice treating patients withcancer andblood diseases. Our...
?
mi
from
Bloomington, IL
Click here to add this to my saved trials
100 E Idaho St
Boise, Idaho 83712
(208) 381-2711
Principal Investigator: Gary E. Goodman
Phone: 907-212-6871
Saint Luke's Mountain States Tumor Institute For more than 100 years, St. Luke
?
mi
from
Boise, ID
Click here to add this to my saved trials
Bonne Terre, Missouri 63628
Principal Investigator: James L. Wade
Phone: 309-243-3605
?
mi
from
Bonne Terre, MO
Click here to add this to my saved trials
915 Highland Blvd
Bozeman, Montana 59715
(406) 414-5000
Principal Investigator: Benjamin T. Marchello
Phone: 406-969-6060
Bozeman Deaconess Hospital Bozeman Deaconess Hospital is a Joint Commission certified, licensed Level III trauma...
?
mi
from
Bozeman, MT
Click here to add this to my saved trials
Burbank, California
Principal Investigator: Gary E. Goodman
Phone: 907-212-6871
?
mi
from
Burbank, CA
Click here to add this to my saved trials
Burlington, Massachusetts 01805
Principal Investigator: Krishna S. Gunturu
Phone: 781-744-8027
?
mi
from
Burlington, MA
Click here to add this to my saved trials
210 W Walnut St
Canton, Illinois 61520
309-647-5240
Principal Investigator: James L. Wade
Phone: 309-243-3605
Illinois CancerCare - Canton Illinois CancerCare is one of the largest private oncology and hematology...
?
mi
from
Canton, IL
Click here to add this to my saved trials
Canton, Ohio 44708
Principal Investigator: Mitchell Haut
Phone: 888-293-4673
?
mi
from
Canton, OH
Click here to add this to my saved trials
211 Saint Francis Drive
Cape Girardeau, Missouri 63703
573-331-3000
Principal Investigator: James L. Wade
Phone: 309-243-3605
Saint Francis Medical Center Saint Francis Medical Center is a 282-bed facility serving more than...
?
mi
from
Cape Girardeau, MO
Click here to add this to my saved trials
789 Mt Auburn Rd
Cape Girardeau, Missouri 63703
(573) 519-4725
Principal Investigator: James L. Wade
Phone: 309-243-3605
Southeast Cancer Center SoutheastHEALTH is a far-reaching network of providers and facilities including Southeast Hospital...
?
mi
from
Cape Girardeau, MO
Click here to add this to my saved trials
Carbondale, Illinois 62902
Principal Investigator: James L. Wade
Phone: 309-243-3605
?
mi
from
Carbondale, IL
Click here to add this to my saved trials
Carterville, Illinois 62918
Principal Investigator: James L. Wade
Phone: 309-243-3605
?
mi
from
Carterville, IL
Click here to add this to my saved trials
160 S Adams St
Carthage, Illinois 62321
(217) 357-6877
Principal Investigator: James L. Wade
Phone: 309-243-3605
Illinois CancerCare - Carthage Illinois CancerCare, P.C. is a comprehensive practice treating patients withcancer andblood...
?
mi
from
Carthage, IL
Click here to add this to my saved trials
Centerville, Ohio 45459
Principal Investigator: Howard M. Gross
Phone: 937-775-1350
?
mi
from
Centerville, OH
Click here to add this to my saved trials
Centerville, Ohio 45459
Principal Investigator: Howard M. Gross
Phone: 937-775-1350
?
mi
from
Centerville, OH
Click here to add this to my saved trials
Centralia, Illinois 62801
Principal Investigator: James L. Wade
Phone: 309-243-3605
?
mi
from
Centralia, IL
Click here to add this to my saved trials
Centralia, Washington 98531
Principal Investigator: Gary E. Goodman
Phone: 907-212-6871
?
mi
from
Centralia, WA
Click here to add this to my saved trials
505 S Plummer Ave
Chanute, Kansas 66720
(620) 431-7580
Principal Investigator: Shaker R. Dakhil
Phone: 316-268-5374
Cancer Center of Kansas, PA - Chanute Dr. H.E. Hynes founded Cancer Center of Kansas,...
?
mi
from
Chanute, KS
Click here to add this to my saved trials
303 East Superior Street
Chicago, Illinois 60611
Principal Investigator: Victoria M. Villaflor
Phone: 312-695-1301
?
mi
from
Chicago, IL
Click here to add this to my saved trials
Cincinnati, Ohio 45236
Principal Investigator: Howard M. Gross
Phone: 937-775-1350
?
mi
from
Cincinnati, OH
Click here to add this to my saved trials
Clackamas, Oregon 97015
Principal Investigator: Gary E. Goodman
Phone: 907-212-6871
?
mi
from
Clackamas, OR
Click here to add this to my saved trials
9280 SE Sunnybrook Blvd #100
Clackamas, Oregon 97015
(503) 513-3300
Principal Investigator: Gary E. Goodman
Phone: 907-212-6871
Clackamas Radiation Oncology Center State-of-the-art technology and compassionate care come together at Clackamas Radiation Oncology...
?
mi
from
Clackamas, OR
Click here to add this to my saved trials
Cody, Wyoming 82414
Principal Investigator: Benjamin T. Marchello
Phone: 406-969-6060
?
mi
from
Cody, WY
Click here to add this to my saved trials
Coeur d'Alene, Idaho 83814
Principal Investigator: Benjamin T. Marchello
Phone: 406-969-6060
?
mi
from
Coeur d'Alene, ID
Click here to add this to my saved trials
1500 West Poplar Avenue
Collierville, Tennessee 38017
?
mi
from
Collierville, TN
Click here to add this to my saved trials
Coos Bay, Oregon 97420
Principal Investigator: Gary E. Goodman
Phone: 907-212-6871
?
mi
from
Coos Bay, OR
Click here to add this to my saved trials
Corona, California 92879
Principal Investigator: Mihaela C. Cristea
Phone: 800-826-4673
?
mi
from
Corona, CA
Click here to add this to my saved trials
Danville, Illinois 61832
Principal Investigator: James R. Egner
Phone: 630-978-6212
?
mi
from
Danville, IL
Click here to add this to my saved trials
1 Wyoming St,
Dayton, Ohio 45409
(937) 208-8000
Principal Investigator: Howard M. Gross
Phone: 937-775-1350
Miami Valley Hospital Miami Valley Hospital (MVH) is passionate about providing the most recent medical...
?
mi
from
Dayton, OH
Click here to add this to my saved trials
2222 Philadelphia Dr
Dayton, Ohio 45406
(937) 734-2612
Principal Investigator: Howard M. Gross
Phone: 937-775-1350
Good Samaritan Hospital - Dayton Good Samaritan Hospital (GSH) is passionate about providing the most...
?
mi
from
Dayton, OH
Click here to add this to my saved trials
Dayton, Ohio 45415
?
mi
from
Dayton, OH
Click here to add this to my saved trials
?
mi
from
Dayton, OH
Click here to add this to my saved trials
210 West McKinley Avenue
Decatur, Illinois 62526
?
mi
from
Decatur, IL
Click here to add this to my saved trials
4160 John R St #2122
Detroit, Michigan 48201
(313) 833-1785
Wayne State University/Karmanos Cancer Institute Karmanos is based in southeast Michigan, in midtown Detroit, and...
?
mi
from
Detroit, MI
Click here to add this to my saved trials
2799 W Grand Blvd
Detroit, Michigan 48202
(313) 916-2600
Principal Investigator: Ding Wang
Phone: 313-576-9363
Henry Ford Hospital Founded in 1915 by auto pioneer Henry Ford and now one of...
?
mi
from
Detroit, MI
Click here to add this to my saved trials
2020 Central Ave
Dodge City, Kansas 67801
(620) 227-2488
Principal Investigator: Shaker R. Dakhil
Phone: 316-268-5374
Cancer Center of Kansas, PA - Dodge City Dr. H.E. Hynes founded Cancer Center of...
?
mi
from
Dodge City, KS
Click here to add this to my saved trials
Edmonds, Washington 98026
Principal Investigator: Gary E. Goodman
Phone: 907-212-6871
?
mi
from
Edmonds, WA
Click here to add this to my saved trials
Effingham, Illinois 62401
Principal Investigator: James L. Wade
Phone: 309-243-3605
?
mi
from
Effingham, IL
Click here to add this to my saved trials
Effingham, Illinois 62401
Principal Investigator: James R. Egner
Phone: 630-978-6212
?
mi
from
Effingham, IL
Click here to add this to my saved trials
700 West Central
El Dorado, Kansas 67042
(316) 889-0099
Principal Investigator: Shaker R. Dakhil
Phone: 316-268-5374
Cancer Center of Kansas, PA - El Dorado Dr. H.E. Hynes founded Cancer Center of...
?
mi
from
El Dorado, KS
Click here to add this to my saved trials
101 S Major St
Eureka, Illinois 61530
309-467-2371
Principal Investigator: James L. Wade
Phone: 309-243-3605
Illinois CancerCare - Eureka Illinois CancerCare is one of the largest private oncology and hematology...
?
mi
from
Eureka, IL
Click here to add this to my saved trials
1717 13th St
Everett, Washington 98201
(425) 297-5500
Principal Investigator: Gary E. Goodman
Phone: 907-212-6871
Providence Regional Cancer Partnership Founded in 2007, the Providence Regional Cancer Partnership is the result...
?
mi
from
Everett, WA
Click here to add this to my saved trials
801 Broadway North
Fargo, North Dakota 58122
Principal Investigator: Preston D. Steen
Phone: 712-252-0088
?
mi
from
Fargo, ND
Click here to add this to my saved trials
Fargo, North Dakota 58122
?
mi
from
Fargo, ND
Click here to add this to my saved trials
Findlay, Ohio 45840
Principal Investigator: Howard M. Gross
Phone: 937-775-1350
?
mi
from
Findlay, OH
Click here to add this to my saved trials
Findlay, Ohio 45840
Principal Investigator: Howard M. Gross
Phone: 937-775-1350
?
mi
from
Findlay, OH
Click here to add this to my saved trials
1900 S Main St
Findlay, Ohio 45840
(419) 423-4500
Principal Investigator: Howard M. Gross
Phone: 937-775-1350
Blanchard Valley Hospital For more than 100 years, Blanchard Valley Hospital has made quality care...
?
mi
from
Findlay, OH
Click here to add this to my saved trials
Fort Scott, Kansas 66701
(620) 223-8589
Principal Investigator: Shaker R. Dakhil
Phone: 316-268-5374
Cancer Center of Kansas - Fort Scott Dr. H.E. Hynes founded Cancer Center of Kansas,...
?
mi
from
Fort Scott, KS
Click here to add this to my saved trials
Fort Wayne, Indiana 46845
Principal Investigator: Krishna A. Rao
Phone: 217-545-5817
?
mi
from
Fort Wayne, IN
Click here to add this to my saved trials
Franklin, Ohio 45005
Principal Investigator: Howard M. Gross
Phone: 937-775-1350
?
mi
from
Franklin, OH
Click here to add this to my saved trials
One Medical Center Drive
Franklin, Ohio 45005
(513) 424-2111
Principal Investigator: Howard M. Gross
Phone: 937-775-1350
Atrium Medical Center - Middletown Regional Hospital Atrium Medical Center (Atrium) is built on the...
?
mi
from
Franklin, OH
Click here to add this to my saved trials
Fruitland, Idaho 83619
Principal Investigator: Gary E. Goodman
Phone: 907-212-6871
?
mi
from
Fruitland, ID
Click here to add this to my saved trials
Galesburg, Illinois 61401
Principal Investigator: James L. Wade
Phone: 309-243-3605
?
mi
from
Galesburg, IL
Click here to add this to my saved trials
3315 N Seminary St
Galesburg, Illinois 61401
309-344-9269
Principal Investigator: James L. Wade
Phone: 309-243-3605
Illinois CancerCare - Galesburg Illinois CancerCare, P.C. is a comprehensive practice treating patients withcancer andblood...
?
mi
from
Galesburg, IL
Click here to add this to my saved trials
Garden City, Kansas 67846
Principal Investigator: Allen M. Chen
Phone: 913-945-7552
?
mi
from
Garden City, KS
Click here to add this to my saved trials
Grand Rapids, Michigan 49503
Principal Investigator: Kathleen J. Yost
Phone: 616-391-1230
?
mi
from
Grand Rapids, MI
Click here to add this to my saved trials
100 Michigan St NE
Grand Rapids, Michigan 49503
(616) 391-1774
Principal Investigator: Kathleen J. Yost
Phone: 616-391-1230
Spectrum Health at Butterworth Campus Butterworth Hospital is one of four facilities that make up...
?
mi
from
Grand Rapids, MI
Click here to add this to my saved trials
Great Bend, Kansas 67530
?
mi
from
Great Bend, KS
Click here to add this to my saved trials
1117 29th St S
Great Falls, Montana 59405
(406) 771-7300
Principal Investigator: Benjamin T. Marchello
Phone: 406-969-6060
Benefis Healthcare- Sletten Cancer Institute Benefis Hospitals has 516 beds at its two campuses (that...
?
mi
from
Great Falls, MT
Click here to add this to my saved trials
1400 29th Street South
Great Falls, Montana 59405
406-454-2171
Principal Investigator: Benjamin T. Marchello
Phone: 406-969-6060
Great Falls Clinic Founded in 1917, the Great Falls Clinic is the fourth oldest medical...
?
mi
from
Great Falls, MT
Click here to add this to my saved trials
Greenville, Ohio 45331
Principal Investigator: Howard M. Gross
Phone: 937-775-1350
?
mi
from
Greenville, OH
Click here to add this to my saved trials
835 Sweitzer St
Greenville, Ohio 45331
(937) 548-1141
Principal Investigator: Howard M. Gross
Phone: 937-775-1350
Wayne Hospital Stretching back to our roots nearly 100 years ago, Wayne HealthCare has always...
?
mi
from
Greenville, OH
Click here to add this to my saved trials
2220 Canterbury Drive
Hays, Kansas 67601
785.623.5000
Principal Investigator: Allen M. Chen
Phone: 913-945-7552
Hays Medical Center Hays Medical Center is a private, not-for-profit hospital formed by the 1991...
?
mi
from
Hays, KS
Click here to add this to my saved trials
Helena, Montana 59601
Principal Investigator: Benjamin T. Marchello
Phone: 406-969-6060
?
mi
from
Helena, MT
Click here to add this to my saved trials
Hendersonville, North Carolina 28971
Principal Investigator: James E. Radford
Phone: 828-696-4716
?
mi
from
Hendersonville, NC
Click here to add this to my saved trials
Hendersonville, North Carolina 28791
Principal Investigator: James E. Radford
Phone: 828-696-1341
?
mi
from
Hendersonville, NC
Click here to add this to my saved trials
Honolulu, Hawaii 96813
Principal Investigator: Jeffrey L. Berenberg
Phone: 808-586-2979
?
mi
from
Honolulu, HI
Click here to add this to my saved trials
1301 Punchbowl St
Honolulu, Hawaii 96813
(808) 538-9011
Principal Investigator: Jeffrey L. Berenberg
Phone: 808-586-2979
Queen's Medical Center The Queen's Medical Center, located in downtown Honolulu, Hawaii, is a private,...
?
mi
from
Honolulu, HI
Click here to add this to my saved trials
888 S King St
Honolulu, Hawaii 96813
(808) 522-4000
Principal Investigator: Jeffrey L. Berenberg
Phone: 808-586-2979
Straub Clinic And Hospital Founded in 1921, Straub Clinic & Hospital is a fully integrated...
?
mi
from
Honolulu, HI
Click here to add this to my saved trials
Honolulu, Hawaii 96813
Principal Investigator: Jeffrey L. Berenberg
Phone: 808-586-2979
?
mi
from
Honolulu, HI
Click here to add this to my saved trials
Honolulu, Hawaii 96817
Principal Investigator: Jeffrey L. Berenberg
Phone: 808-586-2979
?
mi
from
Honolulu, HI
Click here to add this to my saved trials